Management of anemia during adjuvant therapy in patients with gynecologic malignancies
ZHOU Nian
ZHANG Guo-nan
Abstract：Anemia frequently occurs in gynecologic malignancy patients undergoing adjuvant therapy,with iron-deficiency anemia(IDA)being the most prevalent.Anemia reduces patients' tolerance to treatment,leading to therapy delays,dose reductions,or even discontinuation.This may result in chemotherapy resistance and decreased radiotherapy sensitivity.Correcting anemia can improve prognosis,so standardized anemia management is essential.Common therapeutic approaches include iron supplementation,erythropoiesis-stimulating agents(ESAs),and blood transfusions.Among these,third-generation intravenous iron preparations have emerged as a new option in the anemia management in adjuvant therapy for patients with gynecological malignancies due to their rapid iron repletion,reduced transfusion risks,and the convenience of single-dose administration.
Keywords：gynecologic malignanciescancer-related anemiachemotherapy-induced anemiairon-deficiency anemiaintravenous iron
Publication Date：2025-10-02
Online Publishing Date：2025-11-19(First online date of this platform, not the publication date of the document)
Pages：4( 972-975 )